HAYWARD, Calif., March 8 /PRNewswire/ -- Zyomyx, Inc., a leader in chip- based bioanalytical technologies, today announced it has been selected by Imperial College London’s CD4 Initiative to work on a new treatment management tool for HIV/AIDS patients in developing countries. The Company will co- develop a novel test for counting CD4+ T-lymphocytes in blood, a parameter that is a key input into the treatment algorithm for HIV/AIDS. The new test will be designed to be suitable for widespread use in resource-poor countries.
Zyomyx will receive milestone-dependent payments from Imperial College over the next four years for the development of this technology. Upon successful completion of the development program, the Company intends to manufacture the resulting product for global release. Imperial College’s CD4 Initiative is funded by the Bill & Melinda Gates Foundation.
“The absence of inexpensive, rapid, and robust CD4 counting tools jeopardizes global initiatives for fighting AIDS. The Zyomyx product development infrastructure and suite of proprietary assay and surface technologies are ideally suited for the development and launch of an advanced but simple and inexpensive CD4 cell counting product that will meet the demanding specifications for use in developing countries,” said Peter Wagner, Ph.D., President and CEO of Zyomyx. “We are grateful to the CD4 Initiative at Imperial College for inviting us to be part of this strong collaborative effort which will enable us to fully develop our initial CD4 technologies to product level.”
About Zyomyx
Zyomyx, Inc., a privately held biotechnology company based in Hayward, California, is an innovator in the development and commercialization of proprietary bioanalytical platforms based on its expertise in assay development, surface chemistry, and microsystem technologies. The company’s offerings include product development programs, intellectual property out- licensing, and R&D collaborations. For more information, visit the Zyomyx website at www.zyomyx.com.
Zyomyx, Inc.
CONTACT: Peter Wagner, Ph.D., CEO & President of Zyomyx, Inc.,+1-510-265-8001, or pwagner@zyomyx.com
Web site: http://www.zyomyx.com//
